.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
QuintilesIMS
Novartis
Cerilliant
Medtronic
Moodys
Queensland Health
Teva
McKinsey

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,420,390

« Back to Dashboard

Details for Patent: 6,420,390

Title: Heteroarylpiperidines and their use as antipsychotics
Abstract:Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Inventor(s): Strupczewski; Joseph T. (Flemington, NJ), Glamkowski; Edward J. (Warren, NJ), Chiang; Yulin (Covent Station, NJ), Bordeau; Kenneth J. (Kintnersville, PA), Nemoto; Peter A. (Raritan, NJ), Tegeler; John J. (Bridgewater, NJ)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Filing Date:Apr 19, 2000
Application Number:09/556,116
Claims:1. N-(2,3-Epoxypropyl)4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine and its pharmaceutically acceptable acid addition salts.

2. 1-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-propanone and its pharmaceutically acceptable acid addition salts.

3. 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-metho xyphenyl]-2-hydroxyethanone and its pharmaceutically acceptable acid addition salts.

4. A pharmaceuticlal composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 3.

5. A depot pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 3 wherein the compound contains a hydroxy group which has been acylated.

6. The depot pharmaceutical composition of claim 5, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group.

7. The depot pharmaceutical composition of claim 5 which contains a pharmaceutically acceptable oil.

8. The depot pharmaceutical composition of claim 7, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil and esters of fatty acids and polyfunctional alcohols.

9. The depot pharmaceutical composition of claim 6 which contains a pharmaceutically acceptable oil.

10. The depot pharmaceutical composition of claim 9, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil and esters of fatty acids and polyfunctional alcohols.

11. A method for providing a long acting antipsychotic effect which comprises injecting into a mammal an amount of the composition of claim 5 sufficient to produce a long acting antipsychotic effect.

12. An antipsychotic composition which comprises the compound of claim 3 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.

13. A method of treating psychoses which comprises administering to a mammal a psychoses-treating amount of a compound of claim 3.

14. An antipsychotic composition which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.

15. A method of treating psychoses which comprises administering to a mammal a psychoses-treating amount of a compound of claim 1.

16. An antipsychotic composition which comprises the compound of claim 2 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.

17. A method of treating psychoses which comprises administering to a mammal a psychoses-treating amount of a compound of claim 2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Medtronic
Moodys
Harvard Business School
Merck
AstraZeneca
Accenture
UBS
Colorcon
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot